Alvotech And DKSH Partner On Adalimumab In Asia

After Deals In Canada, Europe And Israel, Alvotech Targets Asia

 
• By Akriti Seth

Alvotech has partnered with DKSH to bring its high-concentration Humira rival to Asia. The Alvogen sister company plans to file the adalimumab biosimilar with the EMA and FDA in the second half of 2020.

Globe_Asia
DKSH offers access to up to 36 emerging countries in South-East Asia • Source: Shutterstock

Alvotech is partnering with DKSH, a Swiss market expansion services group established in 36 emerging countries in South-East Asia, for an exclusive license partnership for the commercialization of AVT02, an adalimumab biosimilar, in selected Asia-Pacific markets.

AVT02 is a rival to the 100mg/ml high-concentration version of AbbVie’s Humira

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business